SCHEMBL23907983

SCHEMBL23907983

CSc1nc(OCC(=O)NC23CC4CC(CC(C4)C2)C3)c(F)c(N2CC(F)(F)C2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.38
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MAPT P10636 1/20 0.36
LMNA P02545 1/20 0.36
THRB P10828 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
OPRK1 P41145 1/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PTPRC P08575 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN11 Q06124 1/20 0.35
PTPN13 Q12923 1/20 0.35
PTPN22 Q9Y2R2 1/20 0.35
DHODH Q02127 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23907982 0.87 CNR2 (0.41) ALDH1A1MEN1KMT2ATSHRHPGD
SCHEMBL23884322 0.83 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL23907981 0.82 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL23907977 0.82 ALDH1A1 (0.37) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL23908015 0.80 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL23907995 0.77 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL23900365 0.77 ALDH1A1 (0.38) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL23908010 0.77 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL23907978 0.74 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ATSHRNPSR1
SCHEMBL23907971 0.74 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2024-03-19 US disclosed
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 US disclosed
CN-115916175-A Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses 南方研究院 2023-04-04 CN disclosed
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2023-01-31 US disclosed
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-09 US disclosed
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses SOUTHERN RES INST (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885MEN1 4254/4885KMT2A 2117/4885
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885MEN1 4254/4885KMT2A 2117/4885
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885MEN1 4254/4885KMT2A 2117/4885
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885MEN1 4254/4885KMT2A 2117/4885
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 589/4885MEN1 4347/4885KMT2A 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.